CR20200636A - Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria - Google Patents

Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria

Info

Publication number
CR20200636A
CR20200636A CR20200636A CR20200636A CR20200636A CR 20200636 A CR20200636 A CR 20200636A CR 20200636 A CR20200636 A CR 20200636A CR 20200636 A CR20200636 A CR 20200636A CR 20200636 A CR20200636 A CR 20200636A
Authority
CR
Costa Rica
Prior art keywords
treating
ascorbic acid
combination
antiparasitic agent
quinone compounds
Prior art date
Application number
CR20200636A
Other languages
English (en)
Inventor
Sueli De Oliveira Silva Lautenschlager
Celso Vataru Nakamura
Valdecir Farias Ximenes
Vânia Cristina Desoti
Original Assignee
Ic Medtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ic Medtech Corp filed Critical Ic Medtech Corp
Publication of CR20200636A publication Critical patent/CR20200636A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se proporciona un método para tratar, prevenir o aliviar uno o más síntomas de la enfermedad de Chagas en un sujeto, que comprende admistrarle al sujeto: (i) ácido ascórbico, o un enantiómero simple, una mezcla de enantiómeros, o una mezcla de distereómeros de este; o una sal, solvato o hidrato farcacéuticamente aceptable de este; mezcla de diastereómeros de este, o una sal, solvato, hidrato o profármaco farmacéuticamente aceptable de este; y (iii) un agente parasitario.
CR20200636A 2018-06-06 2019-06-05 Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria CR20200636A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862681500P 2018-06-06 2018-06-06
PCT/US2019/035501 WO2019236656A1 (en) 2018-06-06 2019-06-05 Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease

Publications (1)

Publication Number Publication Date
CR20200636A true CR20200636A (es) 2021-06-10

Family

ID=68769906

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200636A CR20200636A (es) 2018-06-06 2019-06-05 Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria

Country Status (12)

Country Link
US (2) US11872233B2 (es)
AR (1) AR115493A1 (es)
AU (1) AU2019282657B2 (es)
BR (1) BR112020024807A2 (es)
CA (1) CA3101331C (es)
CL (1) CL2020003143A1 (es)
CR (1) CR20200636A (es)
ES (1) ES2811674B2 (es)
MX (1) MX2020013076A (es)
PE (1) PE20212333A1 (es)
PY (1) PY1944026A (es)
WO (1) WO2019236656A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019006593A (es) 2016-12-06 2019-09-13 Ic Medtech Corp Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.
CA3101331C (en) 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease
CN115361945B (zh) * 2020-03-31 2024-11-12 浙江养生堂天然药物研究所有限公司 药物组合及其用途
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468414B1 (en) 2001-02-16 2002-10-22 Hydro-Quebec Method of purification of a redox mediator before electrolytic regeneration thereof
US7091241B2 (en) 2001-06-01 2006-08-15 Summa Health System Nontoxic potentiation/sensitization of cancer therapy by supplementary treatment with combined vitamins C and K3
CA2689717C (en) 2006-06-16 2016-10-18 Summa Health System Non-toxic anti-cancer drug combining ascorbate, magnesium and a naphthoquinone
WO2009035908A1 (en) 2007-09-11 2009-03-19 Wyeth Compositions and their use for the treatment of protozoal infections comprising metaflumi zone
WO2009063044A1 (en) 2007-11-16 2009-05-22 Pharmaq As Treatment of parasite diseases using vitamin k3
CN105232532A (zh) 2009-07-20 2016-01-13 萨马保健系统公司 维生素c和维生素k的组合及其用途
CA2805745C (en) 2010-07-19 2019-01-15 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
KR101926320B1 (ko) 2010-08-04 2018-12-06 펠피큐어 파마슈티걸즈 아이엔씨 전립선 암종의 치료를 위한 병용 요법
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
EP3490543A4 (en) * 2016-08-01 2020-04-01 IC-Medtech Corp. ASCORBIC ACID, QUINONE COMPOUND AND SODIUM GLUCOSE CO-TRANSPORTER INHIBITOR FOR THE TREATMENT OF CANCER.
CA3101331C (en) 2018-06-06 2023-12-19 IC-MedTech Corp. Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease

Also Published As

Publication number Publication date
PE20212333A1 (es) 2021-12-14
AR115493A1 (es) 2021-01-27
US20210361666A1 (en) 2021-11-25
ES2811674B2 (es) 2024-02-07
US20240165084A1 (en) 2024-05-23
ES2811674R1 (es) 2021-09-20
US12295957B2 (en) 2025-05-13
BR112020024807A2 (pt) 2021-03-02
US11872233B2 (en) 2024-01-16
CA3101331C (en) 2023-12-19
CL2020003143A1 (es) 2021-06-11
AU2019282657B2 (en) 2024-10-17
ES2811674A2 (es) 2021-03-12
AU2019282657A1 (en) 2020-12-10
CA3101331A1 (en) 2019-12-12
WO2019236656A1 (en) 2019-12-12
PY1944026A (es) 2021-10-27
MX2020013076A (es) 2021-03-02

Similar Documents

Publication Publication Date Title
PH12022550584A1 (en) Pyridine oxynitride, preparation method therefor and use thereof
CR20200636A (es) Compuestos de ácido ascórbico y quinona en combinación con un agente antiparasitorio para el tratamiento de una enfermedad parasitoria
MX2022002415A (es) Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
PH12018501537A1 (en) Benzopyrazole compounds and analogues thereof
PH12017501570B1 (en) Bicyclic ketone sulfonamide compounds
TN2012000421A1 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
NZ627274A (en) Anesthetic compounds and related methods of use
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2021013576A (es) Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
ZA202000028B (en) Use of vibegron to treat overactive bladder
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
NZ754944A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
MX2022003845A (es) Tratamientos cognitivos medicinales.
MX2025005846A (es) Compuestos moduladores de nmda negativos y métodos de uso de estos.
PH12021552953A1 (en) Tricyclic compounds
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
MX2019000413A (es) Inhibidores de triptofano 2,3-dioxigenasa.
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
MX2019006593A (es) Compuestos de acido ascorbico y quinona para el tratamiento de la enfermedad de chagas.
PH12021550248A1 (en) Borate of azetidine derivative
MX2023009620A (es) Metodos terapeuticos.
EA202190865A1 (ru) Комбинированная терапия для лечения рака